BioSpace News Archive

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that management will participate in five upcoming investor conferences.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for rare diseases, reported business highlights and financial results for the third quarter ended September 30, 2023.

BioCryst Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Chimerix reported financial results for the third quarter ended September 30, 2023 and provided an operational update.

Foghorn® Therapeutics Inc. provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended September 30, 2023.

Purple Biotech Ltd. announced that the China National Intellectual Property Administration has granted a new patent for maintaining a pharmaceutical composition of NT219 in its active form.

Bio-Techne Corporation announced that Asuragen, a Bio-Techne brand, will present new data on clinical laboratory testing solutions related to cystic fibrosis variant detection, cancer monitoring, resolving conventionally inaccessible, disease-causing genes, and more at the upcoming meeting of the Association for Molecular Pathology, to be held November 14-18 in Salt Lake City, Utah.

Evogene Ltd. announced that it will release its financial results for the third quarter of 2023, on Wednesday, November 15, 2023.

Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the quarter ended September 30, 2023.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2023.